Classification of early-stage colon cancer with Immunoscore®: clinical evidence and case studies.
Future Oncol
; 18(5): 613-623, 2022 Feb.
Article
en En
| MEDLINE
| ID: mdl-34904905
Plain language summary Immunoscore® is a digital pathology diagnostic test that is used in addition to standard tools for assessing the severity and aggressiveness of tumors in patients with early-stage colon cancer. Immunoscore helps clinicians decide whether chemotherapy would be appropriate in these cases and, if so, for what duration. The test is currently used for patients with stage II or stage III colon cancer to guide treatment and is a good indicator of prognosis in colon cancers, helping to identify which patients are at a higher risk of tumor recurrence and which patients might benefit most from chemotherapy. Immunoscore is also a reliable and precise test, even when performed on different portions of a tumor sample.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inmunoensayo
/
Neoplasias del Colon
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Turquía